Nektar Therapeutics - huge potential with promising results

[SeekingAlpha]

Biopharma company Nektar has the most interesting setup I have ever seen—the reason why the stock is currently so cheap can be found in its peculiar history and an ongoing lawsuit against Eli Lilly. Nektar accuses them of intentionally sabotaging the clinical data of their drug, which caused the company to nearly go bankrupt and almost prevented the drug from being brought to market at all. Here is an introduction to Nektar:

Nektar Therapeutics is developing a drug called rezpegaldesleukin (Rezpeg), which is based on the activation and expansion of the body’s own regulatory T cells (Treg). Treg cells are a key part of the immune system’s balance, and their significance in treating autoimmune diseases is considered one of the most promising approaches in the field—the 2025 Nobel Prize in Medicine was awarded to Treg researchers.

Rezpeg has already passed Phase 2b clinical trials in two different I&I (Inflammation & Immunology) indications—atopic dermatitis and alopecia areata—demonstrating promising efficacy and safety results. The company’s main goal is to develop Rezpeg into a next-generation treatment for several autoimmune diseases, and the program is currently being expanded to include conditions such as Type 1 diabetes, where a Phase 2 trial is underway. Additionally, the company has communicated interest in expanding the development program to asthma, as clinical trials for atopic dermatitis showed promising signs of symptom improvement in patients who also suffered from asthma.

* Atopic dermatitis is a massive and underserved market (>80 million patients) with significantly fewer treatment options than comparable diseases.

* The market is estimated to grow into a market of over $50 billion, making it one of the largest opportunities in immunology.

* Current standard treatments offer limited efficacy and durability, which is why the majority of patients still suffer from symptoms.

* There is a significant gap in safe and effective alternatives after first-line treatments, and no clear second-line standard of care exists.

* Rezpeg offers a new mechanism of action based on Treg cells, which differs from competitors utilizing the IL-4/13 pathway.

* Clinical results show competitive efficacy and a strong position among non-IL4/13 treatments.

* Rezpeg has a clean safety profile with no significant safety concerns in a sample of over 1,000 patients.

* The drug allows for quarterly dosing (4 injections per year), which is considerably more convenient than current treatments.

* Maintenance phase results suggest long-lasting and deepening treatment responses over time, which could significantly increase the drug’s value.

* Atopic dermatitis patients switch treatments frequently, creating a favorable market environment for new and differentiated drugs.

* NKTR’s current valuation of approximately $2 billion (enterprise value) seems low relative to the drug’s potential multi-billion dollar sales potential and peer companies.

* Furthermore, Rezpeg has expansion potential into many other I&I indications.

[kimsku]

Great opening. It’s easy to get enthusiastic about the company thanks to the good Phase 2 results. The low valuation is a bit of a matter of opinion at this point, however; there is an ongoing legal battle against a pharma giant in the US. If they lose, the legal costs alone will likely be substantial, not to mention if they have to pay damages for wrongful accusations. A victory, of course, would certainly provide a boost to the share price.

Additionally, Phase 3 has not yet begun, so marketing authorization and commercialization will happen in 2029 at the earliest, meaning the journey is still very long. In principle, the cash balance should last until then, provided there are no surprises.

[SeekingAlpha]

Yes, it is definitely worth following the progress of the legal battle. The court proceedings begin in September (though I believe Eli Lilly will not let it get that far, but rather a deal will be made before then). The format of the litigation is a jury trial, which is exactly the type that big pharma companies want to avoid, as laypeople assess who is at fault. Big pharma companies are not held in high regard among citizens in the US. Eli Lilly has already admitted that the data analysis was completely botched – Nektar claims it was done intentionally, as EL had acquired another drug within the same indication and therefore did not want this one on the market. It would be a massive reputational blow if EL loses this in court. EL has also already dropped all counterclaims, so if EL wins the case, Nektar will only be responsible for its own legal fees.

Here is Nektar’s pipeline and the size of the G7 markets. (Note: AA looks small because there have been no effective drugs on the market). I personally cannot name another biopharma with a market cap under 2B that has this many promising (unique MoA - Mechanism of Action) indications in the pipeline.